NSCLC Patients With EGFR Activating Mutation Who Responded to Erlotinib in the First Line Treatment and Developed an Acquired Resistance
| Drug | Drug Name | Drug Description |
|---|
| Drug | Drug Name | Target | Type |
|---|
| Drug | Drug Name | Phase | Status | Count |
|---|
| Drug | Drug Name | Drug Description |
|---|
| Drug | Drug Name | Target | Type |
|---|
| Drug | Drug Name | Phase | Status | Count |
|---|